DOCSLIB.ORG

COVID Vaccine Quick Reference Chart for Timeline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID Vaccine Quick Reference Chart for Timeline Pfizer-BioNTech Moderna Johnson & Johnson Novavax Oxford-AstraZeneca Sputnik V CureVac Sinopharm's BBIBP-CorV MOA mRNA vaccine mRNA vaccine Adenovirus vector vaccine Protein-based vaccine Adenovirus vector vaccine Adenovirus vector vaccine mRNA vaccine Inactivated virus Dosing 2 doses, 21 days apart 2 doses, 28 days apart 1 dose 2 doses, one month apart 2 doses, three months apart Sputnik Light requires one dose. 2 doses, four weeks apart 2 doses, three weeks apart Schedule The vaccine has been In a press release, the Gamaleya National D shown to be 89.3% effective Center of Epidemiology and Microbiology in in large-scale UK trials. Moscow claimed a large-scale Russian e 72% in the U.S. and 66% globally 76% in a U.S. study against Significantly, it is the first study saw 92% efficacy for its vaccine. t against moderate-to-severe symptomatic COVID-19; 100% 95% at least 7 days after 94.1% at least 14 days jab shown to be effective However, other scientists have voiced Efficacy results are presumed to 78% according to the World Health Efficacy disease; 85% effective against effective severe disease; 85% a dose 2 after dose 2 against the new UK variant concerns this claim is based on too few be released in May 2021. Organization severe disease, 28 days after a efficacy against symptomatic of COVID-19 in such a trial. cases. Although the vaccine was trialled on i single dose. COVID-19 in those 65+ 96% against original 18,000 people, the efficacy claim has been l coronavirus, 86% against B. based on an analysis of only 39 individuals s 1.1.7, 49% against B.1.351. to test positive with coronavirus. Frozen; can be stored Ultra-cold freezer Stable at regular fridge refrigerated for up to Stable in refrigerator for at Sputnik Light is refrigerator stable at 36.5 - Storage required, for up to 6 temperature for up to 3 months Regular fridge temperature Stable in refrigerator for 3 months Refrigerator stable at 36.5 - 46.4ºF. 30 days prior to first least 6 months 46.4ºF. months and stable for 2 years at -4ºF. use. U.K. EUA Dec 2, 2020 Jan 8, 2021 delayed, but in prog In progress Dec 30, 2020 A Phase 3 trial in progress, U.S. EUA Dec 11, 2020 Dec 18, 2020 Feb 27, 2021 delayed, but in prog u EUA expected in May 2021 t E.U. EUA Dec 21, 2020 Jan 6, 2021 Mar 11, 2021 *exploratory talks Jan 29, 2021 h Russia Nov 2020 o Canada Dec 23, 2020 r W.H.O. May 7, 2021 i March 2021: PAUSED - Some EU countries decided to restrict z the use of AstraZeneca's a 4/13/2021: PAUSED out of vaccine to older citizens after t "abundance of caution" due to cases of blood clots were blood clot and low platelet reports assessed in younger people. i Countries include France, o Germany, and Denmark, n amongst others. 4/23/2021: pause lifted March/April 2021: pause lifted A Authorized for ages 18+, with Authorized for ages Authorized for ages 12+ Authorized for ages 18+ age limitations in EU certain Approved for ages 18+ g 18+ e countries 3/16/2020: Moderna Q1 begins Phase 1 human clinical trial for their 2020 mRNA COVID-19 vaccine in the U.S. Q2 4/29/2020: Human trials 4/29/2020: Researchers begin Phase 2020 begin in Germany. 1 trial. 5/12/2020: Moderna receives Fast Track designation from the FDA to proceed with a Phase 2 study of their vaccine. 5/1/2020: Novavax 5/18/2020: Moderna announces a combined releases interim data Phase 1/2 clinical trial, with May 2020: CureVac announces 5/5/2020: Pfizer and from their Phase 1 phase 1 starting in Austraia positive results for vaccine BioNtech Dose 1st U.S. clinical trial, stating and Phase 2 to be candidate in preclinical Participants. plans for a Phase 3 conducted in multiple expieriments. trial to begin in July. countries following the 5/29/2020: Moderna results of Phase 1. announces purpose and enrollment of Phase 2 clinical trial. Enrollment was completed July 8. D e v e l o p m e n t H i g h l i g h t s Pfizer-BioNTech Moderna Johnson & Johnson Novavax Oxford-AstraZeneca Sputnik V CureVac Sinopharm's BBIBP-CorV 6/6/2020: Researchers confirm June 2020: The Gamaleya Research promising results from trial in Institute begins clinical trials for a monkeys, stating the vaccine is combination adenovirus vaccine. genetically stable and seems to be safe in animals. 7/14/2020: Moderna publishes interim results of their Phase 1 7/20/2020: AstraZeneca's trial in The New 7/30/2020: Single dose of J&J Phase 1 human clinical trial 7/18/20: Phase 3 trial begins in the Q3 England Journal of vaccine candidate demonstrates results are published in The UAE, with subsequent Phase 3 trials Medicine. robust protection in pre-clinical Lancet; results show vaccine 2020 in Peru and Morocco. 7/27/2020: Moderna studies. is safe and create an immune begins Phase 3 clinical response. trial, enrolling 30,000 adults across the U.S. 8/4/2020: Novavax announces the results of Phase 1 of the Phase 1/2 clinical trial stating the vaccine was "generally well- 8/12/2020: Peer- tolerated and elicited robust Reviewed Phase 1/2 antibody responses." Data Published in Nature 8/24/2020: Novavax Magazine. announces the initation of Phase 2 of its Phase 1/2 clinical trials. Participants are enrolled in both the U.S. and Australia. 9/3/2020: Vaccine prevents severe clinical disease in pre- clinical studies. 9/23/2020: D Global Phase 3 'Ensemble' e Clinical Trials Begin 9/2/2020: Novavax v 9/25/2020: Interim results from announces publication of Phase 1/2a clinical trial support Phase 1 results in The New e further clinical development of England Journal of 9/4/2020: The Gamaleya Research Institute vaccine, but Phase 3 PAUSED Medicine. publishes the results of their Phase 1/2 l 9/1/2020: Phase 3 clinical trials after a serious medical event 9/24/2020: Novavax clinical trial, announcing their Sputnik V o begin in the U.S. experienced by 1 study announces initiation of vaccine yielded antibodies with only mild p participant. Phase 3 clincial trial using side effects. m 9/25/2020: Interim results from 10,000 participants across Phase 1/2a clinical trial support the U.K. (enrollment is e further clinical development of completed 11/30/2020). n vaccine, but Phase 3 PAUSED after a serious medical event t experienced by 1 study participant. H 10/17/2020: Research published in i The Lancet shares the results of a Q4 10/23/2020: Phase 3 Ensemble 10/17/2020: Phase 2/3 trial launches in Phase 1/2 trial, showing the vaccine g 2020 Trial resumes. India. stimulates the production of antibodies h and does not cause serious adverse l effects. 11/23/2020: AstraZeneca and 11/16/2020: Moderna i the University of Oxford 11/18/20: Pfizer and releases preliminary announce the initial results of 11/11/2020: The Russian Direct Investment g BioNTech conclude data from Phase 3 11/16/2020: Announcement of the Phase 3 clinical trials in the Fund announces that Sputnik's Phase 3 November 2020: CureVac reports h Phase 3 Study, meeting clinical trial, stating second Phase 3 clinical trial to U.K., Brazil, and South Africa. clinical trial demonstrated high efficacy positive interim Phase 1 data for all primary and their vaccine is 94.5% observe the use of two doses t The study showed the vaccine rates, determining a 92% efficacy rate for its COVID-19 vaccine candidate. secondary efficacy effective. The data is versus one. was safe and effective. Data the Sputnik V vaccine. s endpoints. released in full on from the study was published November 30. 11/19 in The Lancet. 12/2/2020: Moderna files to test their vaccine in adolescents 12/10/20: Pfizer and 12-18 years of age. December 2020: The Gamaleya Reserch 12/23/2020: CureVac begins BioNTech Announce Moderna announces 12/28/2020: Novavax Institute and AstraZeneca decide to Phase 3 trial using 36,500 Publication of Results the clinical trial on announces initiation of combine vaccines in an effort to increase participants across Europe and 12/30/2020: Sinopharm states their from Phase 3 Trial in March 10, 2021. Phase 3 efficacy trial in U.S. the efficacy of the AstraZeneca vaccine, Latin America. Results are vaccine has an efficacy rate of 79%. The New England 12/31/2020: Moderna and Mexico. with clinical trials beginning in February presumed to be released in May Journal of Medicine. publishes results of 2021. 2021. Phase 3 trial in The New England Journal of Medicine. D e v e l o p m e n t H i g h l i g h t s Pfizer-BioNTech Moderna Johnson & Johnson Novavax Oxford-AstraZeneca Sputnik V CureVac Sinopharm's BBIBP-CorV 1/13/2021: Interim Phase 1/2a Data published in New England Journal of Medicine 1/29/2021: Johnson & Johnson 1/13/2021: Interim Phase Q1 announce that their Phase 3 trial 1/2a Data published in New 2021 show their vaccine to be safe and England Journal of effective; the results of the trial Medicine. are published in The New England Journal of Medicine April 29, 2021. 2/25/21: Pfizer and 2/3/2021: Oxford and 2/12/2021: The European Union BioNTech Initiate a Study 2/4/2020: Novavax applies AstraZeneca publish more data 2/2/2021: The Gamaleya Research begins a "rolling review" process as Part of Broad 2/21/2021: Johnson & Johnson for emergency use from clinical trials regarding Institute, in part with Russia’s Ministry of of the Phase 3 trial, in order to Development Plan to announce upcoming clinical trial authorization with FDA, efficacy and prevention.
Load more

Recommended publications
  • Microsoft Outlook
    Morris, Max From: Morris, Max Sent: Monday, March 22, 2021 11:38 PM To: Morris, Max Subject: 03/22/2021 Coronavirus Daily Recap This email is provided for informational, non-commercial purposes only. Use or reliance on the information contained in this email is at your sole risk. This email is not provided by or affiliated in any way with Ally Financial Inc. These updates are being shared to multiple organizations, individuals and lists who/which are bcc’d. Best effort we are sending Daily updates during the business week, typically in the evening, a Weekend Recap on Monday mornings, and any significant breaking news events provided anytime. Please note some numbers included in the Statistics and news stories come from various sources and so can vary as they are constantly changing and not reported at the same time. All communications are TLP GREEN and can be shared freely. Know someone who might want to be added to our Updates? Of course ask them first, and then have them send us an email to [email protected]. Live the message, share the message: Be safe – Stay home and limit travel as much as possible, self-quarantine if you or any members of your family are or may be sick, if you go out wear your mask – the right way, ensure safe social distancing, and practice good hygiene – wash your hands, avoid touching your face, and sanitize used items and surfaces. Need to find a vaccine? Here are a few good sites and resources we have come across that may help: CDC Vaccine Finder – https://vaccinefinder.org/ [Free government website where users can search for pharmacies and providers that offer vaccinations, currently limited number of states but expanding] Dr.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • National Emergency Management Organisation (Nemo) Ministry of National Security St
    NATIONAL EMERGENCY MANAGEMENT ORGANISATION (NEMO) MINISTRY OF NATIONAL SECURITY ST. VINCENT AND THE GRENADINES WEST INDIES Tel: 784-456-2975, Fax: 784-457-1691, Email: [email protected] or [email protected] ______________________________________________________________________________ ___________________________________________________________________________________________________________________ HEALTH SERVICES SUBCOMMITTEE PROTOCOL FOR THE ENTRY OF FULLY VACCINATED TRAVELLERS TO ST. VINCENT AND THE GRENADINES – revised 10/08/2021 AIM: The safe entry of travellers to St. Vincent and the Grenadines in a manner that reduces the risk of the importation and subsequent transmission of COVID-19 in St. Vincent and the Grenadines. OBJECTIVES: 1. To establish the risk of the arriving traveller introducing new COVID-19 cases to SVG; 2. To minimize exposure of residents of SVG to new COVID-19 cases; 3. Early identification of potential exposure to COVID-19 and 4. Early containment of new COVID-19 cases. ESTABLISH RISK OF ARRIVING TRAVELLER: The arriving traveller will: 1. Complete the Pre-Arrival Form available at health.gov.vc And the Port Health Officer will: 1. Review Port Health form for each arriving passenger. 1 PHASED PROCESS OF ENTRY OF FULLY VACCINATED TRAVELERS TO ST. VINCENT AND THE GRENADINES: TESTING & QUARANTINE: PHASE #16 - Commencing Wednesday, August 11, 2021: 1. Where ‘Fully Vaccinated Travelers’ are those persons who: a. Have completed a vaccination regimen with one of the following COVID-19 vaccines recognized by the Ministry of Health, Wellness and the Environment of St Vincent and the Grenadines: i. AstraZeneca – Oxford AstraZeneca (Vaxzevria), COVISHIELD, AstraZeneca COVID-19 vaccine by SK Bioscience; ii. Pfizer-BioNTech COVID-19 vaccine; iii. Moderna COVID-19 vaccine; iv.
    [Show full text]
  • Comparative Characteristics of the Main Coronavirus Vaccines
    Acta Scientific MICROBIOLOGY (ISSN: 2581-3226) Volume 4 Issue 9 September 2021 Editorial Comparative Characteristics of the Main Coronavirus Vaccines Pavel F Zabrodskii* Received: June 23, 2021 Saratov Medical University "REAVIZ", Saratov, Russian Federation Published: August 01, 2021 *Corresponding Author: Pavel F Zabrodskii, Saratov Medical University "REAVIZ", © All rights are reserved by Pavel F Saratov, Russian Federation. Zabrodskii. Since the beginning of the epidemic, vaccine development has been a priority for all developed countries. According to WHO (26 adenovirus rather than human adenovirus should reduce the risk virus. The fact that the vaccine was developed using chimpanzee January 2021), more than 60 vaccines worldwide are already in of allergic reactions and severe side-effects. However, the disadvan- clinical trials. More than 170 are being tested on animals. There tage of this product, as with all vector vaccines, is that the technol- ogy itself is new and has not previously been used in health care. One of the pluses for vector drug manufacturers is their speed of are 22 vaccines that have made it through the final phase of testing. creation. The vaccine is registered for use in the European Union. It The vaccine, developed by US company “Pfizer” and its German is licensed for emergency use in another 20 countries. clinical trials ended on 9 November 2020. In addition to EU coun- partner “BioNTech”, has been registered first in the EU. Phase III - ceutical company Sinovac Biotech, which has shown controversial tries, the vaccine is used in Australia, Saudi Arabia, Switzerland, “CoronaVac” is an inactivated vaccine from Chinese biopharma - Norway, Iceland, Serbia and some other countries.
    [Show full text]
  • The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia's Vaccine
    Article The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia’s Vaccine Rollout Slower than That of Other Nations? Elza Mikule 1,*,† , Tuuli Reissaar 1,† , Jennifer Villers 1,† , Alain Simplice Takoupo Penka 1,† , Alexander Temerev 2 and Liudmila Rozanova 2 1 Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland; [email protected] (T.R.); [email protected] (J.V.); [email protected] (A.S.T.P.) 2 Institute of Global Health, University of Geneva, 1202 Geneva, Switzerland; [email protected] (A.T.); [email protected] (L.R.) * Correspondence: [email protected] † These authors contributed equally. Abstract: The emergence of the SARS-CoV-2 pandemic in the beginning of 2020 led to the deployment of enormous amounts of resources by different countries for vaccine development, and the Russian Federation was the first country in the world to approve a COVID-19 vaccine on 11 August 2020. In our research we sought to crystallize why the rollout of Sputnik V has been relatively slow considering that it was the first COVID-19 vaccine approved in the world. We looked at production capacity, at the number of vaccine doses domestically administered and internationally exported, and at vaccine hesitancy levels. By 6 May 2021, more first doses of Sputnik V had been administered Citation: Mikule, E.; Reissaar, T.; abroad than domestically, suggesting that limited production capacity was unlikely to be the main Villers, J.; Takoupo Penka, A.S.; reason behind the slow rollout. What remains unclear, however, is why Russia prioritized vaccine Temerev, A.; Rozanova, L.
    [Show full text]
  • Building Visualizations to Uncover Insights in Clinical Trial and Pipeline Data
    Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Matt Eberle, Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. Diane Webb, President and Co-Founder, BizInt Solutions, Inc. Wednesday, March 24, 2021, 2:00 pm ET This session will start momentarily…. Webinar Host Susie Corbett PHT Chair Pharmaceutical & Health Technology Community https://connect.sla.org/pht/home Matt Eberle Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. [email protected] Following over ten years of experience at Wyeth, Pfizer and Sunovion as a Senior Information Scientist and Pharmaceutical Information Analyst, since 2013 Matt has helped BizInt customers use the BizInt Smart Charts and VantagePoint tools to create new solutions to address their challenges and problems. Matt lives outside Boston, MA. Diane Webb President and Co-Founder, BizInt Solutions, Inc. [email protected] Diane has over 30 years of experience managing the development of software tools to analyze and present competitive intelligence information, with a focus on drug pipeline, clinical trial and patent data. In 1996 Diane and John Willmore started BizInt Solutions to develop and market the BizInt Smart Charts product family. Diane & John live near Seattle, WA, with their current pack of four longhaired dachshunds. Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Part I: Dashboard visualizations and initial challenges PHT Pharma
    [Show full text]
  • COVID-19 Situation Report 474
    For citation: Centre for Infectious Disease Epidemiology and Research-NUS. COVID-19 Situation Report 474. 30 July 2021 July 30 COVID-19 Situation Report 474 Centre for Infectious Disease Epidemiology and Research (CIDER) For citation: Centre for Infectious Disease Epidemiology and Research-NUS. COVID-19 Situation Report 474. 30 July 2021 s i. Background In December, China notified the World Health Organization (WHO) of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, previously known as 2019-nCoV and now called SAR-CoV-2; The new name of the disease has also been termed COVID-19, as of 11th February 2020. Although the virus is presumed zoonotic in origin, person-to-person spread is evident. Screening of travellers, travel bans and quarantine measures are being implemented in many countries. Despite these precautions, it is anticipated that more cases will be seen both inside China and internationally. The WHO declared the outbreak of COVID-19 constitutes a Public Health Emergency of International Concern on 30 January. On 11 March, 2020, WHO declared the coronavirus outbreak a pandemic as the global death toll rose above 4,600 and the number of confirmed cases topped 125,000. This report aims to update Global Risk Assessment, Global Epidemiology, Quarantine Orders, Travel Ban/Advisory by countries, WHO’s and CDC’s Guidance and Protocols and Scientific publication on a daily basis. New updates in the tables are bolded. 1 | P a g e Centre for infectious di sease epidemiology and research For citation: Centre for Infectious Disease Epidemiology and Research-NUS.
    [Show full text]
  • STI Policies in Russia Amid COVID-19 3
    ___________________________________________________________________________ 2021/SOM3/PPSTI/007 Agenda Item: 10d Science, Technology and Innovation Cooperation for the Sustainable and Resilient System After COVID-19 from the Russian Perspective Purpose: Information Submitted by: Russia 18th Policy Partnership on Science, Technology and Innovation Meeting 25-26 August 2021 STI cooperation for the Sustainable and resilient system after COVID-19 from the Russian perspective Karine Haji, researcher, Institute for International Economics and Finance Russian Foreign Trade Academy, Russia Plan of the presentation 1. COVID-19 changes everything 2. STI policies in Russia amid COVID-19 3. How can STI help? The opportunities for future recovery 2 COVID-19 changes everything GLOBAL PHENOMENON The World Health Organisation announced the pandemic just in three months after the first case detected COMMON SET OF Social distancing; MEASURES Lockdown; Travel restrictions; Medical check-ups and speed tests; Mapping and tracking of COVID-19 infected people and their contacts. MORE DIGITAL STI are vital instruments in all speres of human life and society 3 STI policies in Russia amid COVID-19 RAPID E-commerce (including in traditional sectors); DIGITALISATION E-government; remoted work and education. “Sputnik V”, “Sputnik Light”, «EpiVacCorona» and VACCINATION «CoviVac». LEGAL To support STI amid COVID-19. GROUND IT- Two sets of supportive measures. INDUSTRY SUPPORT Olympic movement among children and youth EDUCATIO more places for STI specialists in
    [Show full text]
  • Coronavirus Vaccine Tracker
    https://nyti.ms/2MHNdRL U.S.A. World Health Coronavirus Vaccine Tracker By Carl Zimmer, Jonathan Corum and Sui-Lee Wee Updated April 5, 2021 PHASE 1 PHASE 2 PHASE 3 AUTHORIZED APPROVED ABANDONED 50 35 23 5 8 4 Vaccines Vaccines Vaccines Vaccines Vaccines Vaccines testing safety in expanded in large-scale in early or approved abandoned and dosage safety trials efficacy tests limited use for full use after trials Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 86 vaccines in clinical trials on humans, and 23 have reached the final stages of testing. At least 77 preclinical vaccines are under active investigation in animals. New additions and recent updates April 5 The Walter Reed Army Institute of Research enters Phase 1. April 5 Japanʼs KM Biologics begins Phase 1/2. April 2 Franceʼs OSE Immunotherapeutics enters Phase 1. March 31 The Pfizer-BioNTech vaccine is highly effective in adolescents. March 31 Some Johnson & Johnson doses are delayed by a U.S. factory mix-up. March 30 Chinaʼs Jiangsu Rec-Biotechnology enters Phase 1. March 27 Turkeyʼs Middle East Technical and Bilkent University begin Phase 1. March 25 A vaccine from Chinaʼs Zhongyianke Biotech enters Phase 2. March 23 U.S. officials question the completeness of AstraZenecaʼs trial results. March 23 Daiichi Sankyo and the University of Tokyo enter Phase 1/2. March 22 AstraZenecaʼs vaccine is found to be 79% effective in a large U.S.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 19 Luglio 2021
    Coronavirus: quello che c’è da sapere – 19 luglio 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................26 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................26 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................32 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................48 I bambini sono più soggetti all’infezione? .............................................14 Quali sono i rischi sanitari legati all’epidemia? .....................................60
    [Show full text]
  • Current Scenario of Sars-Coronavirus 2: Epidemiology; Post-Covid-19 and Global Impacts
    CURRENT SCENARIO OF SARS-CORONAVIRUS 2: EPIDEMIOLOGY; POST-COVID-19 AND GLOBAL IMPACTS Vishnu Priya Sampatha*, Prasannaraj Govindarajb, Ramasamy Subbiah c, Makesh Mohand Address(es): a State-Key Laboratory for Mechanical Behavior of Materials, School of Material Science & Engineering, Xi'an Jiaotong University, Xi'an 710049, China. b Neurochemistry Laboratory, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore 632004, Tamil Nadu, India. c Cardiac Hypertrophy Laboratory, Department of Molecular Biology, School of Biological Sciences, Madurai Kamaraj University, Madurai 625021, Tamil Nadu, India. d Department of Physics, National Institute of Technology, Karnataka (NITK) Surathkal 575025, Karnataka, India. *Corresponding author: [email protected] https://doi.org/10.15414/jmbfs.4066 ARTICLE INFO ABSTRACT Received 11. 12. 2020 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a highly contagious strain of coronavirus that causes Coronavirus Disease 2019 (COVID-19) infection, which has distressed the world's health and wealth. This Global Pandemic outbreak has affected Revised 17. 6. 2021 public health enormously at various customs. The investigation of SARS-CoV-2 is still at infancy; however, based on the available Accepted 29. 6. 2021 reports, this review gives an overview of the epidemiology, genomic landscape, diversity of SARS-CoV-2, viral genome pathogenic Published xx.xx.201x interactions, associating factors for COVID-19 infections, post-COVID-19, disease manifestations with their comorbidities, the major obstacles and the preventive measures along with current vaccine strategies of SARS-CoV-2. This review also summarizes all the Regular article relevant evidence of COVID-19 illness, which can provide valuable information on the SARS-CoV-2 genome and its mode of action strategies, thus delivering additional knowledge about COVID-19.
    [Show full text]
  • Single-Dose Sputnik Light Could Be First Single-Dose Vaccine Launched
    04/06/2021 Single-dose Sputnik Light could be first single-dose vaccine launched in India My Account HOME LATEST TRENDING PREMIUM e-paper Get APP Home >News >India >Single-dose Sputnik Light could be first single-dose vaccine launched in India Single-dose Sputnik Light could be first single-dose vaccine launched in India OPEN APP Sputnik Light has already been approved and trials are already started in some other countries (MINT_PRINT) 1 min read . Updated: 02 Jun 2021, 10:08 AM IST Shalini Bhardwaj, ANI Sputnik Light is a single-dose vaccine that can be useful to boost the country's requirement and target to increase maximum vaccination drive There is a possibility of a speedy launch of single-dose Covid-19 vaccine Sputnik Light in India, and an application seeking regulatory approval for the jab is expected to be filed soon, the sources said on Tuesday. According to the sources Dr. Reddy's in talks with the Government of India to bring Russia's Sputnik Light vaccine to India. MORE FROM THIS SECTION See All https://www.livemint.com/news/india/singledose-sputnik-light-could-be-first-single-dose-vaccine-launched-in-india-11622607843495.html 1/4 04/06/2021 Single-dose Sputnik Light could be first single-dose vaccine launched in India My Account HOME LATEST TRENDING PREMIUM AIIMS entrance exam: This airline will launch Air travel restrictions Gujarat eases Covid-19 Student unions want Supersonic Jet: Sea-npaper Get AcoPPuld be eased, depending restrictions, all offices to The Sputnik Light can become the first single-dose vaccine to be launched in India.
    [Show full text]